Actively Recruiting
Open-Label Study of Dupilumab Injection for Safety and Pharmacokinetics in Children and Adolescents with Prurigo Nodularis
Led by Sanofi · Updated on 2026-10-13
18
Participants Needed
15
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a Phase 3, multicenter, open-label study to evaluate the pharmacokinetics and safety of dupilumab in children and adolescents aged 6 months to under 18 years who have prurigo nodularis. This condition requires participants to have a clinical diagnosis with specific lesion and itch severity criteria to be included. The study aims to better understand how dupilumab behaves in the body and its safety profile in this population. Participants will receive dupilumab administered subcutaneously, with dosing based on their weight and age. The study includes three distinct periods a screening period lasting 2 to 4 weeks, a treatment period of 24 weeks during which dupilumab is given, and a post-intervention follow-up period lasting 16 weeks. The total participation time is approximately 42 to 44 weeks, and there will be six planned study visits for each participant. During the study, participants and caregivers will complete daily symptom e-diaries to track itch severity and other symptoms. Researchers will monitor the concentration of dupilumab in the blood from Day 1 through Week 40, as well as the incidence of any treatment-related adverse events and the development of anti-drug antibodies. Safety and effectiveness will be assessed throughout the treatment and follow-up periods, ensuring thorough observation over the entire study duration.
CONDITIONS
Brief Title
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
Research Team
T
Trial Transparency email recommended (Toll free for US & Canada)
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here